Interview with Winette van der Graaf: enhanced patient participation in trials may help make cancer research more heterogeneous

ESMO Congress 2022. Winette van der Graaf, president of EORTC, talks about the importance and challenges of placing the patient at the center of clinical trials. She states that patients are usually highly motivated to participate in clinical trials. However, several challenges, such as logistics, communication issues, and geographic distance to a trial center, may prevent them from doing so. Moreover, the current strict enrolment criteria often exclude older patients from clinical trials. The result is that trials tend to be overly homogeneous, thus limiting the generalisability of the data. With an aging population, we need more elderly patients to participate in clinical trials. Read the full article here.

Back to news list

Related News

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023

  • EORTC & the Menarini Group Launch New Clinical Trial in Early-Stage Breast Cancer

  • EORTC’s presence at ESMO 2023

  • The EU funded project LEGATO officially started

  • EORTC strategic meeting with Middle Eastern Ambassadors

  • EORTC Quality of Life Group projects to be presented at ISOQOL 2023